• Western blot analysis of lysates from 293T cells, primary antibody was diluted at 1:1000, 4°C over night

Anti-PYHIN1 antibody (338-388 aa) (STJ193945)

SKU:
STJ193945

Current Stock:
Host: Rabbit
Applications: WB
Reactivity: Human/Mouse
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit polyclonal antibody anti-Pyrin and HIN domain-containing protein 1 (338-388 aa) is suitable for use in Western Blot research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Formulation: Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide.
Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration: 1 mg/mL
Dilution Range: WB 1:500-2000
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: PYHIN1
Gene ID: 149628
Uniprot ID: IFIX_HUMAN
Immunogen Region: 338-388 aa
Specificity: This antibody detects endogenous levels of IFIX at Human/Mouse
Immunogen: Synthesized peptide derived from the human IFIX at the amino acid range 338-388
Function Major mediator of the tumor suppressor activity of IFN in breast cancer cells. Promotes ubiquitination and subsequent degradation of MDM2, which leads to p53/TP53 stabilization. Promotes ubiquitination and subsequent degradation of HDAC1, which in turn enhances maspin expression, and impairs invasive activity of cancer cells.
Protein Name Pyrin And Hin Domain-Containing Protein 1
Interferon-Inducible Protein X
Cellular Localisation Isoform 1: Nucleus
Nucleoplasm
Isoform 3: Nucleus
Isoform 5: Nucleus
Nucleus Speckle
Alternative Antibody Names Anti-Pyrin And Hin Domain-Containing Protein 1 antibody
Anti-Interferon-Inducible Protein X antibody
Anti-PYHIN1 antibody
Anti-IFIX antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance